产品
编 号：F741515
分子式：C43H45BrCl2N3OP
分子量：801.62
分子式：C43H45BrCl2N3OP
分子量：801.62
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2361564-49-8
产品详情
生物活性：
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells.
体内研究：
Mito-LND (7.5?μmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis. Mito-LND also decreases the rate of growth of A549 tumor xenografts.Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells.Animal Model:Athymic nude mice (5 weeks) injected with H2030BrM3 cells
Dosage:7.5?μmol/kg
Administration:Oral gavage; 5 days per week; for 3 consecutive weeks
Result:Significantly decreased tumor progression.
体外研究：
Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 μM and 0.69?μM, respectively.Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 μM and 2.4?μM, respectively in H2030BrM3 cells. Mito-LND (1?μM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells.Mito-LND (2?μM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling.
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells.
体内研究：
Mito-LND (7.5?μmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis. Mito-LND also decreases the rate of growth of A549 tumor xenografts.Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells.Animal Model:Athymic nude mice (5 weeks) injected with H2030BrM3 cells
Dosage:7.5?μmol/kg
Administration:Oral gavage; 5 days per week; for 3 consecutive weeks
Result:Significantly decreased tumor progression.
体外研究：
Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 μM and 0.69?μM, respectively.Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 μM and 2.4?μM, respectively in H2030BrM3 cells. Mito-LND (1?μM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells.Mito-LND (2?μM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备